Cancer Clinical Trials and IMUs Platform Co-lead, Singapore Translational Cancer Consortium;
Deputy Director, Cancer Science Institute of Singapore;
Deputy Director, National University Cancer Institute, Singapore (Research);
Senior Consultant, Department of Hematology-Oncology, National University Cancer Institute, Singapore;
Professor, Department of Pharmacology & Department of Medicine, National University of Singapore;
Group Chief, Physician Leadership and Organisation Development Office, National University Health System, Singapore
Professor Goh Boon Cher received his undergraduate medical education at the National University of Singapore, and joined the Department of Hematology-Oncology, NUH where he completed fellowship in medical oncology, and completed a National Medical Research Council fellowship in clinical pharmacology and phase I clinical trials at the University of Chicago. Professor Goh has established himself as a leading clinician scientist in clinical pharmacology and cancer drug development, and currently serves on several institutional and national research portfolios. He has contributed much to the development of a clinical trial research infrastructure at the NCIS, one of the largest clinical research groups in Singapore, and chaired the Cancer Therapeutics Research Group, an Asia Pacific cancer research group. As a clinician, Professor Goh is well established in the fields of head and neck/lung cancer. As a senior clinician and scientist, he has mentored many clinical oncology and pharmacology fellows, and has been awarded senior clinician scientist from the Biomedical Research Council and the National Medical Research Council since 2005. In addition, he has been competitive in being awarded research grants as principal investigator of both individual project grants and infrastructure grants. Beyond cancer therapeutics, he is also widely published in pharmacogenetics, studying how human genetics affect drug response. Internationally, as a key opinion leader, he has served on advisory boards of several pharmaceutical companies advising on drug development of very novel drugs, and has served on editorial boards of important journals like the Journal of Clinical Oncology and Annals of Oncology. As a responsible member of clinical research, he has also espoused principles of ethics, and served for several terms as Chairman of the Domain Specific Research Board.
Cancer Clinical Trials & IMUs Platform Co-lead, Singapore Translational Cancer Consortium;
Senior Consultant Medical Oncologist, National Cancer Centre Singapore;
Senior Clinician-Scientist, Genome Institute of Singapore
Dr. Daniel Tan has a specialist interest in thoracic, head and neck oncology and cancer drug development. His work is focused on addressing the translational gap between basic science and clinical practice – particularly in improving our understanding of the determinants of response and resistance to targeted therapy and immunotherapy.
In recognition of his research, he received the American Society of Clinical Oncology (ASCO) Merit Award twice, an ASCO Young Investigator Award and the SingHealth GCEO Outstanding Clinician-Researcher Award (2016). In 2019, he was awarded the Daniel C. Idhe Lectureship in Medical Oncology from the International Association for Study of Lung Cancer (IASLC) 2019 for his ‘extensive contributions in the lung cancer arena’. He was twice awarded the Clinician-Scientist Award from the National Medical Research Council of Singapore (NMRC). He has published more than 100 peer-reviewed articles, including top tier journals such as The New England Journal of Medicine, The Lancet, Nature, Nature Genetics, Nature Medicine and Journal of Clinical Oncology.
Dr. Tan received undergraduate training at St Bartholomew’s and Royal London Hospitals in the United Kingdom, obtained First Class honours for an Intercalated BSc in Tumor Biology from University College London (UCL), and undertook a postgraduate fellowship in drug development at the Royal Marsden Hospital. In 2017, he completed his PhD in Cancer Biology from Cancer Science Institute, National University of Singapore.
A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (DT), 2015
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib (DT), 2015
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015
A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations, 2016
A Phase Ib/II Multi-centre, Randomized, Open-label Trial to Compare MSC2156119J combined with Gefitinib Versus Chemotherapy as Second Line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First Line Gefitinib, 2013
A phase I, multi-center, open label dose escalation and expansion study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFR-mut solid malignancies, 2014
A Phase Ib open-label clinical trial of once daily oral treatment of afatinib plus weekly intravenous infusion of BI 836845 in patients with EGFR mutant non-small cell lung cancer with progression following prior EGFR tyrosine kinase inhibitors, 2014